Should I buy or sell ESSA Pharma stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ESSA Pharma in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" EPIX shares. View EPIX analyst ratings or view top-rated stocks .

What is ESSA Pharma's stock price target for 2024?

2 analysts have issued 1-year price objectives for ESSA Pharma's stock. Their EPIX share price targets range from $16.00 to $17.00. On average, they anticipate the company's share price to reach $16.50 in the next twelve months. This suggests a possible upside of 161.1% from the stock's current price. View analysts price targets for EPIX or view top-rated stocks among Wall Street analysts .

How have EPIX shares performed in 2024?

ESSA Pharma's stock was trading at $6.60 at the beginning of the year. Since then, EPIX stock has decreased by 4.2% and is now trading at $6.32. View the best growth stocks for 2024 here .

Are investors shorting ESSA Pharma?

ESSA Pharma saw a drop in short interest in the month of March. As of March 31st, there was short interest totaling 802,800 shares, a drop of 13.5% from the March 15th total of 928,600 shares. Based on an average trading volume of 154,100 shares, the short-interest ratio is currently 5.2 days. View ESSA Pharma's Short Interest .

When is ESSA Pharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our EPIX earnings forecast .

How were ESSA Pharma's earnings last quarter?

ESSA Pharma Inc. (NASDAQ:EPIX) issued its quarterly earnings results on Tuesday, February, 13th. The company reported ($0.14) EPS for the quarter, topping the consensus estimate of ($0.17) by $0.03.

What other stocks do shareholders of ESSA Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ESSA Pharma investors own include RedHill Biopharma (RDHL) , Aurinia Pharmaceuticals (AUPH) , Lipocine (LPCN) , Trevena (TRVN) , Allena Pharmaceuticals (ALNA) , Agile Therapeutics (AGRX) , Biopharmx (BPMX) , Corbus Pharmaceuticals (CRBP) and Heat Biologics (HTBX) .

How do I buy shares of ESSA Pharma?

Shares of EPIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:EPIX

ESSA Pharma (EPIX) Stock Price, News & Analysis

→ Secret Bull Market Starts in This Unusual Sector (From Altimetry) (Ad)

Free EPIX Stock Alerts

$6.32

-0.40 (-5.95%)

(As of 05:21 PM ET)

Compare

Today's Range: $6.18
▼
$7.01
50-Day Range: $6.72
▼
$10.43
52-Week Range: $2.56
▼
$11.67

Volume: 102,387 shs
Average Volume: 138,056 shs
Market Capitalization: $279.60 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $16.50

Get ESSA Pharma alerts:

ESSA Pharma MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 161.1% Upside
$16.50 Price Target
Short Interest: Healthy
1.81% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.97
Based on 3 Articles This Week
Insider Trading: Selling Shares
$11,742 Sold Last Quarter
Proj. Earnings Growth: Decreasing
From ($0.80) to ($1.13) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.85 out of 5 stars

Medical Sector

388th out of 911 stocks

Pharmaceutical Preparations Industry

173rd out of 412 stocks

3.5

Analyst's Opinion

Consensus Rating
ESSA Pharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
ESSA Pharma has received no research coverage in the past 90 days.

4.0

Short Interest

Percentage of Shares Shorted
1.81% of the outstanding shares of ESSA Pharma have been sold short.
Short Interest Ratio / Days to Cover
ESSA Pharma has a short interest ratio ("days to cover") of 5.2.
Change versus previous month
Short interest in ESSA Pharma has recently decreased by 13.55%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
ESSA Pharma does not currently pay a dividend.
Dividend Growth
ESSA Pharma does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for EPIX.

2.8

News and Social Media Coverage

News Sentiment
ESSA Pharma has a news sentiment score of 0.97. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.52 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for ESSA Pharma this week, compared to 0 articles on an average week.
Search Interest
Only 1 people have searched for EPIX on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.
MarketBeat Follows
Only 1 people have added ESSA Pharma to their MarketBeat watchlist in the last 30 days. This is a decrease of -80% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, ESSA Pharma insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $11,742.00 in company stock.
Percentage Held by Insiders
14.70% of the stock of ESSA Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
75.12% of the stock of ESSA Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for ESSA Pharma are expected to decrease in the coming year, from ($0.80) to ($1.13) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of ESSA Pharma is -10.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of ESSA Pharma is -10.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
ESSA Pharma has a P/B Ratio of 1.92. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Altimetry

Secret Bull Market Starts in This Unusual Sector

"We're only at the very beginning of a new wave that could deliver 500%-plus gains in the years to come." In fact, 50 small companies related to this sector have already soared 100% or more in a recent 90-day stretch.

Click for my No. 1 investment, all free of charge, click here.

About ESSA Pharma Stock (NASDAQ:EPIX)

ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company's lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer. It has collaboration agreements with Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.

EPIX Stock Price History

30 days | 90 days | 365 days | Advanced Chart

EPIX Stock News Headlines

April 16, 2024 | americanbankingnews.com

Critical Review: Eli Lilly and Company (NYSE:LLY) & ESSA Pharma (NASDAQ:EPIX)

April 13, 2024 | americanbankingnews.com

ESSA Pharma (NASDAQ:EPIX) Shares Pass Below 50-Day Moving Average of $8.94

April 19, 2024 | Behind the Markets (Ad)

Tiny Biotech Stock Wins $75 Billion Patent

A little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.

April 9, 2024 | finance.yahoo.com

ESSA Pharma to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference

April 9, 2024 | prnewswire.com

ESSA Pharma to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference

April 8, 2024 | finance.yahoo.com

ESSA Pharma (NASDAQ:EPIX) Is In A Strong Position To Grow Its Business

April 7, 2024 | investing.com

Essa Pharma COO sells shares worth over $5,500

April 5, 2024 | morningstar.com

ESSA Pharma Inc EPIX

April 19, 2024 | Behind the Markets (Ad)

Tiny Biotech Stock Wins $75 Billion Patent

March 10, 2024 | finance.yahoo.com

EPIX Jul 2024 7.500 call

March 10, 2024 | finance.yahoo.com

EPIX Jul 2024 12.500 put

March 7, 2024 | prnewswire.com

ESSA PHARMA INC. REPORTS RESULTS OF ANNUAL GENERAL MEETING OF SHAREHOLDERS

February 13, 2024 | benzinga.com

ESSA Pharma: Q1 Earnings Insights

February 13, 2024 | finance.yahoo.com

ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal First Quarter Ended December 31, 2023

February 8, 2024 | finance.yahoo.com

ESSA Pharma Inc Executive Peter Virsik Sells 72,782 Shares

February 6, 2024 | finance.yahoo.com

ESSA Pharma to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

January 22, 2024 | finance.yahoo.com

ESSA Pharma Inc.'s (NASDAQ:EPIX) hedge funds investors lost 12% last week but have benefitted from longer-term gains

December 20, 2023 | finance.yahoo.com

EPIX: Initial Data from Combination Trial of Masofaniten and Enzalutamide Expected in 2024…

December 14, 2023 | benzinga.com

ESSA Pharma Stock (NASDAQ:EPIX) Earnings Dates and Earning Calls

December 12, 2023 | benzinga.com

ESSA Pharma Stock (NASDAQ:EPIX) Dividends: History, Yield and Dates

December 12, 2023 | benzinga.com

Recap: ESSA Pharma Q4 Earnings

December 12, 2023 | finance.yahoo.com

ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Fourth Quarter and Year Ended September 30, 2023

December 11, 2023 | finance.yahoo.com

Bullish ESSA Pharma Insiders Loaded Up On US$1.19m Of Stock

November 24, 2023 | msn.com

ESSA Pharma director Franklin Berger buys common shares worth ~$133.3K

November 21, 2023 | finance.yahoo.com

ESSA Pharma to Present at the Piper Sandler 35th Annual Healthcare Conference

November 8, 2023 | finance.yahoo.com

ESSA Pharma to Present at the Jefferies London Healthcare Conference

October 31, 2023 | finance.yahoo.com

We Think ESSA Pharma (NASDAQ:EPIX) Can Afford To Drive Business Growth

See More Headlines

Receive EPIX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ESSA Pharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/13/2024
Today: 4/19/2024
Next Earnings (Estimated): 5/14/2024
Fiscal Year End: 9/30/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:EPIX
CUSIP: N/A
CIK: 1633932
Web: www.essapharma.com
Phone: 778-331-0962
Fax: 604-738-4080
Employees: 50
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $16.50
High Stock Price Target: $17.00
Low Stock Price Target: $16.00
Potential Upside/Downside: +161.1%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.59)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-26,580,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -17.41%
Return on Assets: -17.04%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 40.74
Quick Ratio: 40.74

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $3.30 per share
Price / Book: 1.92

Miscellaneous

Outstanding Shares: 44,240,000
Free Float: 37,737,000
Market Cap: $279.60 million
Optionable: Optionable
Beta: 1.62

13 Stocks Institutional Investors Won't Stop Buying

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

Dr. David Ross Parkinson M.D. (Age 74)
President, CEO & Director
Comp: $814.15k
Mr. David S. Wood C.M.A. (Age 67)
CPA, CMA, CPA, M.B.A., MBA, Chief Financial Officer
Comp: $590.39k
Mr. Peter A. Virsik M.B.A. (Age 53)
M.S., Executive VP & COO
Comp: $645.95k
Dr. Alessandra Cesano M.D. (Age 63)
Ph.D., Chief Medical Officer & Executive VP
Comp: $623.93k
Chandtip Chandhasin
Executive
Erica Osbourne
Executive
Erin Rudsinski
Executive
Loleta Harris
Executive
Neil Thapar
Executive
Nkengyal Barber
Executive

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

EPIX Stock Analysis - Frequently Asked Questions

Should I buy or sell ESSA Pharma stock right now?: 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ESSA Pharma in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" EPIX shares.
View EPIX analyst ratings or view top-rated stocks.
What is ESSA Pharma's stock price target for 2024?: 2 analysts have issued 1-year price objectives for ESSA Pharma's stock. Their EPIX share price targets range from $16.00 to $17.00. On average, they anticipate the company's share price to reach $16.50 in the next twelve months. This suggests a possible upside of 161.1% from the stock's current price.
View analysts price targets for EPIX or view top-rated stocks among Wall Street analysts.
How have EPIX shares performed in 2024?: ESSA Pharma's stock was trading at $6.60 at the beginning of the year. Since then, EPIX stock has decreased by 4.2% and is now trading at $6.32.
View the best growth stocks for 2024 here.
Are investors shorting ESSA Pharma?: ESSA Pharma saw a drop in short interest in the month of March. As of March 31st, there was short interest totaling 802,800 shares, a drop of 13.5% from the March 15th total of 928,600 shares. Based on an average trading volume of 154,100 shares, the short-interest ratio is currently 5.2 days.
View ESSA Pharma's Short Interest.

When is ESSA Pharma's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our EPIX earnings forecast.
How were ESSA Pharma's earnings last quarter?: ESSA Pharma Inc. (NASDAQ:EPIX) issued its quarterly earnings results on Tuesday, February, 13th. The company reported ($0.14) EPS for the quarter, topping the consensus estimate of ($0.17) by $0.03.
What other stocks do shareholders of ESSA Pharma own?: Based on aggregate information from My MarketBeat watchlists, some companies that other ESSA Pharma investors own include RedHill Biopharma (RDHL), Aurinia Pharmaceuticals (AUPH), Lipocine (LPCN), Trevena (TRVN), Allena Pharmaceuticals (ALNA), Agile Therapeutics (AGRX), Biopharmx (BPMX), Corbus Pharmaceuticals (CRBP) and Heat Biologics (HTBX).
How do I buy shares of ESSA Pharma?: Shares of EPIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:EPIX) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial